Fig. 6: Suggested approach for co-target discovery to more profoundly target the vulnerabilities to reinforced hyperactivation in ERK-associated human cancer.
From: ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework
Figure generated in Biorender.
